Statin Effects on Cognitive Health and Dementia Risk

Statins, widely prescribed for lowering cholesterol and preventing cardiovascular disease, have attracted attention for their potential influence on brain health. Research suggests that beyond lipid-lowering, statins may modulate neuroinflammation, oxidative stress and vascular function, factors implicated in cognitive decline and dementia. Observational studies generally report an association between statin use and reduced risk of Alzheimer’s disease and mild cognitive impairment, whereas findings on vascular dementia and direct cognitive side effects remain mixed. The balance of evidence indicates possible neuroprotective benefits, but also highlights the need to clarify dose, duration, statin type and individual risk profiles through rigorous trials.

Research from Nature Portfolio

A comprehensive meta-analysis has pooled data from longitudinal cohort studies to assess statin use and incident dementia. Results indicate that regular statin therapy is associated with a significant reduction in risk of all-cause dementia, Alzheimer’s disease and mild cognitive impairment, but shows no meaningful effect on vascular dementia. Subgroup analyses reveal that both hydrophilic and lipophilic statins confer protective effects, with hydrophilic agents more consistently linked to lower overall dementia risk and lipophilic agents showing particular benefit for Alzheimer’s disease. This work underscores a class effect of statins on neurodegenerative processes and supports further investigation into lipid-independent mechanisms.

Statin Effects on Cognitive Health and Dementia Risk publication trend

The graph below shows the total number of articles in statin effects on cognitive health and dementia risk across all publications each year (not limited to Nature Index journals).

Technical terms

Blood–brain barrier (BBB): A selective endothelial interface that regulates passage of substances between the bloodstream and the central nervous system. Lipophilicity: The chemical affinity of a compound for lipid environments, influencing its ability to penetrate cell membranes and the BBB. Mild cognitive impairment (MCI): A clinical stage characterised by measurable cognitive decline beyond normal ageing without significant interference in daily activities. Isoprenoids: Lipid metabolites derived from the mevalonate pathway that modify proteins through prenylation and affect intracellular signalling. Amyloid precursor protein (APP): A neuronal membrane protein cleaved to form amyloid β peptides, central to Alzheimer’s disease pathology.

References

1. Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis. Scientific Reports (2018).
2. Statins and cognitive decline in patients with Alzheimer’s and mixed dementia: a longitudinal registry-based cohort study. Alzheimer's Research & Therapy (2023).
3. Do Statins Affect Cognitive Health? A Narrative Review and Critical Analysis of the Evidence. Current Atherosclerosis Reports (2024).
4. The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Translational Neurodegeneration (2018).